Jeffrey S Stonebraker

Global prophylaxis trends in hemophilia: a macroeconomic analysis and its association with world development indicators

John, M. J., Stonebraker, J., Jindal, A., Tootoonchian, E., Pierce, G. P., Gouider, E., … Coffin, D. (2024, November 13). Expert Review of Hematology, Vol. 11.

Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study

Curtis, R., Wu, J., Iorio, A., Frick, N., Nichol, M., Noone, D., … Germini, F. (2024, March 4). Haemophilia, Vol. 3.

Reported prevalence of von Willebrand disease worldwide in relation to income classification

Stonebraker, J. S., Iorio, A., Lavin, M., Rezende, S. M., Srivastava, A., Pierce, G. F., … Makris, M. (2023, June 5). Haemophilia, Vol. 6.

Von Willebrand Disease: Gaining a global perspective

O'Sullivan, J. M., Tootoonchian, E., Ziemele, B., Makris, M., Federici, A. B., Djambas, C. K., … Lavin, M. (2023, May 22). Haemophilia, Vol. 5.

Indicators of care

World Federation of Hemophilia World Congress. Presented at the World Federation of Hemophilia World Congress, Montreal, Canada.

Measuring access in the era of EHLs and Hemlibra (emicizumab vs FVIII equivalence

World Federation of Hemophilia World Congres. Presented at the World Federation of Hemophilia World Congress, Montreal, Canada.

Annual Global Survey: Capturing new products

The World Federation of Hemophilia Twelfth Global Forum on Research and Treatment Products for Bleed Disorders. Presented at the World Federation of Hemophilia Twelfth Global Forum on Research and Treatment Products for Bleed Disorders.

Case Article—Bayer New Drug Development Decision Making

Stonebraker, J. S. (2021, November 3). INFORMS Transactions on Education.

Case—Bayer New Drug Development Decision Making

Stonebraker, J. S. (2021, November 3). INFORMS Transactions on Education.

Converting EHL to SHL: review of clinical and RWE data

European Haemophilia Consortium Workshop in New Technologies. Presented at the European Haemophilia Consortium Workshop in New Technologies.

Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time

Stonebraker, J. S., O'Mahony, B., Noone, D., & Iorio, A. (2021, June 17). Haemophilia, Vol. 6.

Evaluation of the sexual health in people living with hemophilia

Germini, F., Chai‐Adisaksopha, C., Pete, D., Curtis, R., Frick, N., Nichol, M. B., … Iorio, A. (2021, September 19). Haemophilia, Vol. 9.

Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres

Stonebraker, J. S., & Ducore, J. M. (2020, October 4). Haemophilia, Vol. 27.

Non‐severe haemophilia: Is it benign? – Insights from the PROBE study

Chai‐Adisaksopha, C., Noone, D., Curtis, R., Frick, N., Nichol, M. B., Germini, F., … Iorio, A. (2020, September 1). Haemophilia, Vol. 9.

Risk analysis, practice, and considerations in capital budgeting: Evidence from the field for the bio-based industry

Assis, C. A., Suarez, A., Prestemon, J. P., Stonebraker, J., Carrillo, C., Dasmohapatra, S., … Gonzalez, R. (2020, November 4). BioResources, Vol. 16, pp. 19–45.

The World Federation of Hemophilia Annual Global Survey 1999‐2018

Stonebraker, J. S., Bolton‐Maggs, P. H. B., Brooker, M., Evatt, B., Iorio, A., Makris, M., … Tootoonchian, E. (2020, June 4). Haemophilia.

AGS 20th Anniversary Updated estimates of prevalence and prevalence at birth in hemophilia

Presented at the 11th WFH Global Forum on Research and Treatment Products for Bleeding Disorders, Montreal, Canada.

Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males

Iorio, A., Stonebraker, J., Chambost, H., Makris, M., Coffin, D., Herr, C., … Weill, A. (2019, September 9). Annals of Internal Medicine, Vol. 171, pp. 540-+.

Exploring regional variations in the cross‐cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study

Chai‐Adisaksopha, C., Skinner, M. W., Curtis, R., Frick, N., Nichol, M. B., Noone, D., … Iorio, A. (2019, March 12). Haemophilia, Vol. 25, pp. 365–372.

Impact of acute and chronic pain on the EQ-5D: Insights from the PROBE Study

Noone, D., Chai-Adisaksopha, C., Curtis, R., Frick, N., Nichol, M., O’Mahony, B., … Skinner, M. W. (2019, February). Poster presented at the 12th Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Prague, Czech Republic.

Impact on per capita FVIII usage when more countries are buying EHL products and emicizumab

Presented at the 11th WFH Global Forum on Research and Treatment Products for Bleeding Disorders, Montreal, Canada.

Part-Time Employment and Early Retirement in People with Severe Haemophilia: Insights From The PROBE Study

Skinner, M. W., Chai-Adisaksopha, C., Curtis, R., Frick, N., Iorio, A., Nichol, M., … Stonebraker, J. S. (2019, February). Poster presented at the 12th Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Prague, Czech Republic.

Predictors for Acute and Chronic Pain in Patients with Severe Haemophilia in The PROBE Cohort

Noone, D., Chai-Adisaksopha, C., Curtis, R., Frick, N., Nichol, M., O’Mahony, B., … Skinner, M. W. (2019, February). Presented at the 12th Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Prague, Czech Republic.

The Estimated Impact of New Therapies on Factor VIII (FVIII) Use and Product Cost by 2023

International Society of Thrombosis and Haemostasis (ITSH). Poster presented at the International Society of Thrombosis and Haemostasis (ITSH), Melbourne, Australia.

Updated estimates of prevalence and prevalence at birth of hemophilia

Webinar presented at the World Federation of Hemophilia.

Impact of hemophilia on employment - Insights from the PROBE Study

Skinner, M. W., Chai-Adisaksopha, C., Curtis, R., Frick, N., Iorio, A., Nichol, M., … Stonebraker, J. S. (2018, October). Poster presented at the National Hemophilia Foundation (NHF), 2018 Bleeding Disorders Conference.

Latent therapeutic demand model for the immunoglobulin replacement therapy of primary immune deficiency disorders in the USA

Stonebraker, J. S., Hajjar, J., & Orange, J. S. (2018, April 20). Vox Sanguinis.

Modeling latent therapeutic demand for primary immune deficiency disorders in the United States

Presented at the Grifols, Research Triangle Park, NC.

Modeling the future factor usage for Western States Region IX

Presented at the Annual Conference Western States Regional Hemophilia Treatment Centers, Napa Valley, CA.

Occurrence and impact of pain among patients living with hemophilia: An analysis from the patient reported outcomes, burdens and experiences (PROBE) study

Haemophilia, 24(S1), 26–27.

Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire

Chai-Adisaksopha, C., Skinner, M. W., Curtis, R., Frick, N., Nichol, M. B., Noone, D., … Iorio, A. (2018, August 1). BMJ Open, Vol. 8.

Test‐retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains

Chai‐Adisaksopha, C., Skinner, M. W., Curtis, R., Frick, N., Nichol, M. B., Noone, D., … Iorio, A. (2018, December 6). Haemophilia, Vol. 25, pp. 75–83.

The Effect of Inhibitors on Quality of Life and Pain in Adult Patients with Severe Haemophilia in the PROBE Cohort

Research and Practice in Thrombosis Haemostasis, 2(S1), 76–77.

The PROBE Data Dashboard - A new tool for real-time data visualization and analysis of patient reported outcomes

Haemophilia, 24, 181–182.

The PROBE Study –Global burden of bleeding from the mouth in Haemophilia – a call to action

Haemophilia, 24(S5), 66.

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia

Pilot and Feasibility Studies, 4(1), 118–119.

The effect of haemophilia on activities of daily living (ADL)

Poster presented at the European Conference on Rare Disease & Orphan Products.

Burden of Comorbid Diseases in Patients with Hemophilia: The Cross-Sectional Analysis of the Patient Reported Outcomes, Burden and Experiences (PROBE) Study

Blood, 130(S1), 3411.

Burden of Comorbidities in Persons Living with Haemophilia: Insight from the PROBE Phase 2b Study Database

Skinner, M. W., Curtis, R., Frick, N., Iorio, A., Nichol, M., Noone, D., … Stonebraker, J. S. (2017, July 8). Poster presented at the XXVIth Congress of the ISTH, Berlin, Germany.

Burden of comorbidities in persons living with haemophilia: insight from the PROBE phase 2b study database

Research and Practice in Thrombosis Haemostasis, 1(S1), 840–841.

Estimating the global annual bleed rate in haemophilia

Haemophilia, 23, 86–86.

Psychometric Properties of the Patient Reported Outcomes Burdens and Experiences (PROBE) Questionnaire

Blood, 130(S1), 5645.

Sexual Health in Patients with Hemophilia; The Insights from the Patient Reported Outcomes, Burdens and Experiences (PROBE) Study

Blood, 130(S1), 2141.

Test-retest reliability analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) study

Haemophilia, 23(S2), 50–51.

The Global Annual Bleed Rate in Haemophilia: a 2015 Estimate

Research and Practice in Thrombosis Haemostasis, 1(S1), 759–760.

The global annual bleed rate in haemophilia: a 2015 estimate

Thompson, C., Srivastava, A., Skinner, M., Stonebraker, J. S., Epstein, J., Kauf, T., & Valentino, L. A. (2017, July 8). Poster presented at the XXVIth Congress of the ISTH, Berlin, Germany.

VP57 Test-Retest Reliability Analysis Of The Patient Reported Outcomes Burdens And Experiences (PROBE) Study Questionnaire Test-Retest Reliability Analysis Of The PROBE Study Questionnaire

International Journal of Technology Assessment in Health Care, 33(S1), 174–175.

Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data

Haemophilia, 23(1), e1–e7.

Measuring the quality of hemophilia care across different settings: a set of performance indices derived from demographics data

Haemophilia, 22(S4), 26.

Psychometric Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE)

Blood, 128(22), 5964.

The Patient Reported Outcomes Burdens and Experiences (PROBE) Study Phase 1 Methodology and Feasibility Results

Haemophilia, 22(S4), 118–119.

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Study Phase 1 Methodology and Feasibility

Poster presented at the European Conference on Rare Disease & Orphan Products, Edinburgh, United Kingdom.

The Patient Reported Outcomes, Burdens, and Experiences (PROBE) Phase 1

HTAi 2016 Annual Meeting Abstract Book, 63–64.

The Patient Reported Outcomes, Burdens, and Experiences (PROBE) Phase 1 Study Methodology and Feasibility

Haemophilia, 22(S2), 43–44.

The patient reported outcome burdens and experiences (PROBE) study - phase 1 results show PROBE study methodology feasible

Journal of Thrombosis and Haemostasis, 14(S1), 47.

The patient reported outcome burdens and experiences (PROBE) study - phase 1 results show PROBE study methodology feasible

Poster presented at the ISTH Scientific and Standardization Committee Annual Meeting, Montpellier, France.

How to measure progress in the provision of care for hemophilia

The Proceedings of the World Federation of Hemophilia’s Ninth Global Forum on Research and Treatment Products for Bleeding Disorders, 16–17.

A decision analysis model to estimate latent therapeutic demand for immunoglobulin therapy in primary immunodeficiencies

Proceedings of the 15th Meeting of the European Society Immunodeficiencies (ESID), 29–34.

Modeling Primary Immunodeficiency Disease Epidemiology and Its Treatment to Estimate Latent Therapeutic Demand for Immunoglobulin

Party, E. S. I. D. R. W., Stonebraker, J. S., Farrugia, A., Gathmann, B., & Orange, J. S. (2013, December 11). Journal of Clinical Immunology, Vol. 34, pp. 233–244.

Product-Generation Transition Decision Making for Bayer's Hemophilia Drugs: Global Capacity Expansion Under Uncertainty with Supply-Demand Imbalances

Stonebraker, J. S. (2013, October 1). Operations Research, Vol. 61, pp. 1119–1133.

Decision analysis model for estimating latent therapeutic demand for immunoglobulin therapy in primary immune deficiencies

Journal of Clinical Immunology, 32(S1), 18.

A study of reported factor IX use around the world

STONEBRAKER, J. S., BOLTON-MAGGS, P. H. B., BROOKER, M., FARRUGIA, A., & SRIVASTAVA, A. (2011, February 7). Haemophilia, Vol. 17, pp. 446–455.

A study of variations in the reported haemophilia B prevalence around the world

STONEBRAKER, J. S., BOLTON‐MAGGS, P. H. B., SOUCIE, J. M. I. C. H. A. E. L., WALKER, I., & BROOKER, M. (2011, June 7). Haemophilia, Vol. 18, pp. e91–94.

Empirically Investigating the Portfolio Management Process: Findings from a Large Pharmaceutical Company

In Portfolio Decision Analysis (pp. 131–148).

Impact factor as a metric to assess journals where OM research is published

Stonebraker, J. S., Gil, E., Kirkwood, C. W., & Handfield, R. B. (2011, June 2). Journal of Operations Management, Vol. 30, pp. 24–43.

NC State's Supply Chain Resource Cooperative Educates in the Real World

Handfield, R. B., Edwards, S. A., & Stonebraker, J. S. (2011, December 1). INFORMS Journal on Applied Analytics, Vol. 41, pp. 548–563.

Practice Summaries: American Airlines Uses Should-Cost Modeling to Assess the Uncertainty of Bids for Its Full-Truckload Shipment Routes

Bailey, M. J., Snapp, J., Yetur, S., Stonebraker, J. S., Edwards, S. A., Davis, A., & Cox, R. (2011, April 1). INFORMS Journal on Applied Analytics, Vol. 41, pp. 194–196.

A study of reported factor VIII use around the world

STONEBRAKER, J. S., BROOKER, M., AMAND, R. E., FARRUGIA, A., & SRIVASTAVA, A. (2009, October 22). Haemophilia, Vol. 16, pp. 33–46.

A study of variations in the reported haemophilia A prevalence around the world

STONEBRAKER, J. S., BOLTON‐MAGGS, P. H. B., SOUCIE, J. M. I. C. H. A. E. L., WALKER, I., & BROOKER, M. (2009, October 22). Haemophilia, Vol. 16, pp. 20–32.

Factor Usage - Global Data.

The Proceedings of the World Federation of Hemophilia’s Sixth Global Forum on the Safety and Supply of Hemophilia Treatment Products for Bleeding Disorders – Making the Case for Clotting Factor Concentrates, 9–11.

OR Practice—Modeling Potential Demand for Supply-Constrained Drugs: A New Hemophilia Drug at Bayer Biological Products

Operations Research, 57(1), 19–31.

Balancing Environmental and Operational Objectives in Nuclear Refueling Strategies

In W. Edwards, R. F. Miles Jr, & D. von Winterfeldt (Eds.), Advances in Decision Analysis (pp. 564–581).

Understanding the supply-demand-price conundrum in the FVIII market

The Proceedings of the World Federation of Hemophilia’s Fifth Global Forum on the Safety and Supply of Hemophilia Treatment Products, 20–21.

Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand

Haemophilia, 10(1), 18–26.

A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community

Haemophilia, 9(3), 245–250.

Probabilistic Modelling of population-based epidemiology and treatment modalities to determine unconstrained factor VIII demand

Journal of Thrombosis and Haemostasis, 1(S1), P1645.

How Bayer Makes Decisions to Develop New Drugs

Interfaces, 32(6), 77–90.

New York Power Authority Uses Decision Analysis to Schedule Refueling of Its Indian Point 3 Nuclear Power Plant

Interfaces, 31(5), 121–135.

Formulating and solving sequential decision analysis models with continuous variables

IEEE Transactions on Engineering Management, 44(1), 43–53.

Practice Abstract: Decision Analysis Provides Insight to Ford Microelectronics Incorporated

Interfaces, 27(2), 107–111.

It’s Time to Think About Values First

Quality Air Force in the 21st Century: Technology & Innovation 1996 Quality Air Force Symposium Proceedings, 78–88. Maxwell Air Force Base, AL: Air Force Quality Institute.

Can source selection benefit from decision analysis?

Acquisition Research Symposium Proceedings, 287–298.

Simon says: Rational decision-making for source selection

Program Manager: Journal of the Defense Systems Management College, 20(5), 34–40.

The Application of Decision Analysis Methods to Source Selection in the United States Air Force